Biomea Fusion to Participate in Citi's SMID Biotech C-Suite Fireside Chat Series

Rhea-AI Summary

Biomea Fusion (Nasdaq: BMEA) will participate in Citi's SMID Biotech C-Suite Fireside Chat Series on Thursday, October 23, 2025 at 8:00 a.m. PT / 11:00 a.m. ET. A live audio webcast will be available via the company's Investors & Media site and a replay will be posted after the event. The company is a clinical-stage diabetes and obesity firm and will join the session as scheduled.

Investors can access the live audio webcast and subsequent replay at https://investors.biomeafusion.com/news-events/events.

News Market Reaction – BMEA

-0.63%

10 alerts

-0.63% News Effect

+6.6% Peak in 1 hr 13 min

-$633K Valuation Impact

$100M Market Cap

0.9x Rel. Volume

On the day this news was published, BMEA declined 0.63%, reflecting a mild negative market reaction. Argus tracked a peak move of +6.6% during that session. Our momentum scanner triggered 10 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $633K from the company's valuation, bringing the market cap to $100M at that time.

Data tracked by StockTitan Argus on the day of publication.

SAN CARLOS, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that it will participate in Citi’s SMID Biotech C-Suite Fireside Chat Series on Thursday, October 23, 2025, at 8:00 a.m. Pacific Time / 11:00 a.m. Eastern Time.

A live audio webcast of the discussion will be available here or by visiting the Investors & Media section of Biomea’s website at https://investors.biomeafusion.com/news-events/events. A replay of the webcast will be available following the live event.

About Biomea Fusion
Biomea Fusion is a clinical-stage diabetes and obesity medicines company focused on the development of its oral small molecule therapies, icovamenib and BMF-650, for diabetes and obesity. These programs target metabolic disorders, a global health challenge affecting nearly half of Americans and one-fifth of the world’s population. Biomea’s mission is to deliver transformative treatments that restore health for patients living with diabetes, obesity, and related conditions. We aim to cure.

Visit us at biomeafusion.com and follow us on LinkedIn, X and Facebook.

Contact:
Meichiel Jennifer Weiss
Sr. Director of Investor Relations and Corporate Development
ir@biomeafusion.com

FAQ

When will Biomea Fusion (BMEA) participate in Citi's SMID Biotech C-Suite Fireside Chat?

Biomea Fusion will participate on Thursday, October 23, 2025 at 8:00 a.m. PT / 11:00 a.m. ET.

How can I listen to the live Biomea Fusion (BMEA) fireside chat on October 23, 2025?

Listen via the live audio webcast available on Biomea Fusion's Investors & Media events page at https://investors.biomeafusion.com/news-events/events.

Will a replay of the Biomea Fusion (BMEA) Citi fireside chat be available after the live event?

Yes. A replay of the webcast will be available after the live session on the company's events page.

What topics will Biomea Fusion (BMEA) cover during the Citi SMID Biotech fireside chat?

The announcement states the company will participate in the fireside chat; specific discussion topics were not specified.

Is the Biomea Fusion (BMEA) fireside chat audio-only or a video webcast?

The event is described as a live audio webcast.